| Identification | Back Directory | [Name]
KRAS G12C inhibitor 13 | [CAS]
2241719-75-3 | [Synonyms]
KRAS G12C inhibitor 13
KRAS G12C inhibitor 13,KRAS G-12C inhibitor 13
2-Propen-1-one, 1-[7-[6-ethenyl-7-(5-methyl-1H-indazol-4-yl)-2-[[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]oxy]-8-(2,2,2-trifluoroethoxy)-4-quinazolinyl]-2,7-diazaspiro[3.5]non-2-yl]- | [Molecular Formula]
C40H46F3N7O4 | [MDL Number]
MFCD32197242 | [MOL File]
2241719-75-3.mol | [Molecular Weight]
745.83 |
| Chemical Properties | Back Directory | [Boiling point ]
876.6±75.0 °C(Predicted) | [density ]
1.37±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
12.18±0.40(Predicted) |
| Hazard Information | Back Directory | [Uses]
KRAS G12C inhibitor 13 is a KRAS G12C inhibitor extracted from patent WO2018143315A1, compound 30[1]. | [IC 50]
KRas G12C | [References]
[1] KURAMOTO, Kazuyuki, et al. Quinazoline compound. WO2018143315A1. |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|